| CANTARGIA AB |
| Schweden |
| Gesundheit |
| SE0006371126 / A2JAZX |
| 7V3 (Frankfurt) |
| FRA:7V3, ETR:7V3, 7V3:GR |
| - |
| https://cantargia.com/ |
|
Cantargia AB (publ) is a Sweden-based biotechnology company specializing in the development of antibody therapeutics for cancer treatment. Its primary focus is on targeting the Interleukin-1 receptor accessory protein (IL1RAP), a cell-surface recepto..
>Volltext.. |
| 95.48 Mio. EUR |
| 69.53 Mio. EUR |
| 29.69 Mio. EUR |
| 14.78 Mio. EUR |
| 13.78 Mio. EUR |
| 0.06 EUR |
| - |
| 26.42 Mio. EUR |
| 14.07 Mio. EUR |
| 9.41 |
| - |
| - |
| - |
| - |
| - |
| - |
| CANTARGIA |
| 05.04.26 |
|